MHLW Adds Ileus To Side Effects Of Nippon Boehringer Ingelheim’s Spiriva
This article was originally published in PharmAsia News
Japan's Ministry of Health, Labor and Welfare added severe side effects of ileus to package inserts of Nippon Boehringer Ingelheim's Spiriva (tiotropium bromide), a drug to treat chronic obstructive pulmonary disease. Since launched in December 2004, four cases of ileus have been reported. According to the company, an estimated 180,000 patients in Japan are taking the drug every year. (Click here for more - Japanese language
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.